SCHEMBL23728131

SCHEMBL23728131

COc1ccc(CNC(=O)Nc2ccc(C=O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.73
NPC1 O15118 5/20 0.71
RAB9A P51151 4/20 0.71
HDAC1 Q13547 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
HTT P42858 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
POLB P06746 2/20 0.64
SAE1 Q9UBE0 1/20 0.62
UBA2 Q9UBT2 1/20 0.62
ROCK2 O75116 1/20 0.60
NAMPT P43490 5/20 0.59
HIF1A Q16665 1/20 0.56
ALDH1A1 P00352 1/20 0.56
KDM4E B2RXH2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17916794 0.90 SMN1; SMN2 (0.88) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL23747428 0.88 SMN1; SMN2 (0.75) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL23747473 0.85 SMN1; SMN2 (0.79) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL23728203 0.85 SMN1; SMN2 (0.79) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL9836017 0.85 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL16562239 0.83 SMN1; SMN2 (0.77) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL23728118 0.83 SMN1; SMN2 (0.77) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL5427744 0.83 NPC1 (1.00) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL8175404 0.83 RAB9A (0.89) SMN1; SMN2NPC1RAB9AHDAC1HDAC6
SCHEMBL23747392 0.82 SMN1; SMN2 (0.75) SMN1; SMN2NPC1RAB9AHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
CN-115515934-A NAMPT modulators 赛特凯恩蒂克公司 2022-12-23 CN disclosed
EP-4100393-A1 NAMPT MODULATORS Cytokinetics, Inc. (US) 2022-12-14 EP disclosed
WO-2021159015-A1 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-08-12 WO disclosed
WO-2021159015-A1 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 SMN1; SMN2 1161/4885NPC1 463/4885RAB9A 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.